Bosentan
- Generic Name
- Bosentan
- Brand Names
- Stayveer, Tracleer
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O6S
- CAS Number
- 147536-97-8
- Unique Ingredient Identifier
- XUL93R30K2
- Background
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
- Indication
Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
- Associated Conditions
- NYHA Functional Class II-IV Pulmonary arterial hypertension, Ocular Inflammation, Ocular bacterial infections
- Associated Therapies
- -
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-12-31
- Lead Sponsor
- Actelion
- Target Recruit Count
- 151
- Registration Number
- NCT00319111
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
🇫🇷Hôpital Louis Pradel, Lyon, France
🇦🇹General Hospital of Vienna, Vienna, Austria
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Actelion
- Target Recruit Count
- 33
- Registration Number
- NCT00319020
- Locations
- 🇬🇧
The Institute of Child Health, London, United Kingdom
🇺🇸The Children's Hospital Cardiac Care Center, Denver, Colorado, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Bosentan in Children With Pulmonary Arterial Hypertension
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Actelion
- Target Recruit Count
- 36
- Registration Number
- NCT00319267
- Locations
- 🇨🇭
Hopital des Enfants, Geneva, Switzerland
🇮🇹Policlinico S. Orsola-Malpighi, Bologna, Italy
🇬🇧The Institute of Child Health, London, United Kingdom
Open-label Study With Bosentan in Interstitial Lung Disease
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Actelion
- Target Recruit Count
- 132
- Registration Number
- NCT00319033
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Maureen Mayes, MD, Houston, Texas, United States
🇮🇹Ospedale Maggiore, Milano, Italy
Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
- Conditions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Actelion
- Target Recruit Count
- 54
- Registration Number
- NCT00317486
- Locations
- 🇨🇦
The Peter Lougheed Centre, Calgary, Alberta, Canada
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇫🇷Hospital Necker-Enfants Malades, Paris, France
Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Actelion
- Target Recruit Count
- 157
- Registration Number
- NCT00313222
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇩🇪Johannes Gutenberg University Hospital, Mainz, Germany
🇧🇪University Hospital Erasme, Brussels, Belgium
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-01-16
- Lead Sponsor
- Actelion
- Target Recruit Count
- 12
- Registration Number
- NCT00313196
- Locations
- 🇺🇸
Alta Bates Medical Center, Berkeley, California, United States
🇺🇸University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸Temple University Lung Center, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Actelion
- Target Recruit Count
- 14
- Registration Number
- NCT00310830
- Locations
- 🇺🇸
Alta Bates Medical Center, Berkeley, California, United States
🇺🇸SoLUtions/Saint Louis University, St. Louis, Missouri, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Actelion
- Target Recruit Count
- 334
- Registration Number
- NCT00303459
- Locations
- 🇺🇸
Greater Los Angeles VA Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸South Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Actelion
- Target Recruit Count
- 67
- Registration Number
- NCT00302211
- Locations
- 🇺🇸
University of Maryland Hospital, Baltimore, Maryland, United States
🇺🇸GLVA Medical Center, Los Angeles, California, United States
🇺🇸University of Connecticut Health Center, Farmington, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.